STE vs ALC vs THC
161 measures in 16 categories, one definition each, computed from filings and market data.
THC63.3
Tenet Healthcare Corporation
Healthcare · Medical - Care Facilities
$267.25 −2.86%$21.5B mkt cap
Score DNA
Price, rebased to 100 three years ago
STE ALC THC · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry (these stocks sit in different industries). n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | STE | ALC | THC |
|---|---|---|---|
| Insider open-market buys, 180d | 0 | 0 | 0 |
| Insider $ bought, 180d | — | — | — |
| Congress purchases, 180d | 12 | 1 | 0 |
| Last Congress purchase | 2026-09-11 | 2026-03-30 | — |
| 13F net change in holders | — | −24 | — |
| ETFs adding shares, 30d | 998 | 14 | 370 |
| ETFs trimming, 30d | 811 | 7 | 414 |
| Net ETF funds, 30d | +187 | +7 | −44 |
Valuation
16 measures| Measure | STE | ALC | THC |
|---|---|---|---|
| P/E (TTM) | 27.0x | 50.0x | 9.6x
9th
|
| PEG (P/E ÷ 3-yr EPS CAGR) | 0.30 | 2.33 | 0.12
0th
|
| Price / sales | 3.6x
50th
|
3.0x
33rd
|
1.0x
38th
|
| Price / book | 3.0x
33rd
|
1.5x
17th
|
4.6x
68th
|
| Price / tangible book | 14.2x
100th
|
8.1x
75th
|
— |
| Price / free cash flow | 23.5x
50th
|
19.0x
25th
|
7.1x
11th
|
| Price / operating cash flow | 16.8x
50th
|
14.1x
25th
|
5.4x
14th
|
| Enterprise value | $23.3B
83rd
|
$35.8B
100th
|
$32.6B
97th
|
| EV / sales | 3.9x
50th
|
3.3x
33rd
|
1.5x
41st
|
| EV / EBITDA | 14.3x | 14.1x | 6.4x
18th
|
| EV / EBIT | 20.4x | 40.2x | 7.8x
15th
|
| EV / free cash flow | 25.1x
50th
|
21.3x
25th
|
10.8x
19th
|
| Earnings yield | 3.7%
100th
|
2.0%
67th
|
10.4%
94th
|
| FCF yield | 4.3%
67th
|
5.3%
83rd
|
14.0%
91st
|
| Operating cash flow yield | 5.9%
67th
|
7.1%
83rd
|
18.7%
88th
|
| Graham number (per share) | $116.71 | $36.07 | $182.52
95th
|
Profitability (TTM)
12 measures| Measure | STE | ALC | THC |
|---|---|---|---|
| Gross margin | 44.4%
0th
|
56.5%
50th
|
26.9%
47th
|
| EBITDA margin | 27.0%
100th
|
23.6%
83rd
|
23.2%
91st
|
| Operating margin | 18.9%
100th
|
9.9%
67th
|
16.8%
91st
|
| EBIT margin | 18.9%
100th
|
8.2%
67th
|
19.1%
94th
|
| Net margin | 13.3%
83rd
|
5.9%
67th
|
10.3%
88th
|
| NOPAT margin | 14.0%
100th
|
8.6%
67th
|
13.8%
88th
|
| FCF margin | 15.3%
67th
|
15.6%
83rd
|
13.9%
94th
|
| Operating cash flow margin | 21.3%
83rd
|
21.1%
67th
|
18.4%
91st
|
| R&D / revenue | 1.9%
0th
|
13.2%
50th
|
0.0%
0th
|
| SG&A / revenue | 17.5%
0th
|
33.1%
33rd
|
30.3%
88th
|
| Stock comp / revenue | 1.0%
50th
|
— | 0.4%
23rd
|
| Effective tax rate | 25.8%
83rd
|
13.2%
17th
|
17.9%
3rd
|
Returns on capital
11 measures| Measure | STE | ALC | THC |
|---|---|---|---|
| ROE (on average equity) | 11.4%
83rd
|
2.9%
67th
|
53.3%
97th
|
| ROA | 7.6%
83rd
|
2.0%
67th
|
7.5%
66th
|
| ROIC | 9.7%
83rd
|
3.6%
50th
|
19.1%
78th
|
| ROCE | 12.1%
100th
|
3.2%
50th
|
16.6%
75th
|
| Return on tangible assets | 10.8%
100th
|
2.9%
50th
|
14.0%
72nd
|
| Cash ROIC (OCF / invested capital) | 14.7%
67th
|
9.0%
50th
|
25.5%
69th
|
| Gross profitability (GP / assets) | 25.0%
50th
|
19.6%
17th
|
19.1%
28th
|
| ROIC, 3-yr average | 6.1%
100th
|
3.7%
75th
|
13.7%
86th
|
| ROIC, 5-yr average | 5.3%
80th
|
3.2%
60th
|
11.1%
87th
|
| ROE, 5-yr average | 6.9%
100th
|
3.4%
80th
|
56.9%
100th
|
| Incremental ROIC | 163.0%
100th
|
1.1%
20th
|
182.3%
71st
|
Growth
17 measures| Measure | STE | ALC | THC |
|---|---|---|---|
| Revenue growth (TTM YoY) | 8.4%
80th
|
7.8%
60th
|
5.4%
28th
|
| Revenue growth (QoQ) | -6.0%
0th
|
6.4%
67th
|
4.8%
69th
|
| Revenue CAGR, 3 yr | 6.6%
60th
|
6.0%
40th
|
3.1%
11th
|
| Revenue CAGR, 5 yr | 12.1%
40th
|
6.7%
0th
|
2.6%
12th
|
| Gross profit CAGR, 3 yr | 7.3%
80th
|
6.8%
40th
|
-7.3%
8th
|
| Operating income CAGR, 3 yr | 54.8% | 11.8% | 16.1%
63rd
|
| Net income growth (TTM YoY) | 24.5% | -40.4% | 51.0%
72nd
|
| Net income CAGR, 3 yr | 89.0% | 20.9% | 65.0%
100th
|
| EPS growth (TTM YoY) | 25.6% | -39.3% | 65.1%
78th
|
| EPS CAGR, 3 yr | 89.8% | 21.4% | 77.6%
100th
|
| EPS CAGR, 5 yr | 21.2% | 28.7% | 46.2%
100th
|
| FCF growth (TTM YoY) | 1.8% | 4.7% | 93.4%
81st
|
| FCF CAGR, 3 yr | 23.3% | 69.5% | 46.5%
82nd
|
| Operating cash flow CAGR, 3 yr | 16.9% | 25.4% | 31.1%
74th
|
| Book value CAGR, 3 yr | 5.8%
80th
|
3.2%
60th
|
63.0%
95th
|
| Dividend CAGR, 3 yr | 3.7% | 1.9% | — |
| Sustainable growth rate | 7.9% | 2.2% | 53.3%
95th
|
Margin history & stability
7 measures| Measure | STE | ALC | THC |
|---|---|---|---|
| Gross margin, 3-yr average | 43.9%
0th
|
55.6%
60th
|
39.1%
72nd
|
| Operating margin, 3-yr average | 17.6%
100th
|
12.2%
60th
|
20.0%
93rd
|
| Net margin, 3-yr average | 11.0%
100th
|
9.4%
60th
|
10.2%
97th
|
| FCF margin, 3-yr average | 14.6%
60th
|
14.3%
40th
|
10.1%
90th
|
| Revenue stability (0-1) | 0.94
80th
|
0.99
100th
|
0.91
41st
|
| Earnings stability (0-1) | 0.63
100th
|
0.47
40th
|
0.54
79th
|
| Margin stability (0-1) | 0.99
100th
|
0.96
20th
|
0.77
31st
|
Liquidity (latest quarter)
7 measures| Measure | STE | ALC | THC |
|---|---|---|---|
| Cash & short-term investments | $482.3M
83rd
|
$1.5B
100th
|
$2.2B
100th
|
| Net cash (− = net debt) | −$1.6B
33rd
|
−$3.8B
0th
|
−$11.1B
3rd
|
| Working capital | $1.2B
83rd
|
$3.5B
100th
|
$2.3B
100th
|
| Current ratio | 1.91
17th
|
2.09
50th
|
1.41
62nd
|
| Quick ratio | 1.35
33rd
|
1.30
17th
|
1.35
62nd
|
| Cash ratio (cash + ST investments / current liabilities) | 0.38
17th
|
0.46
33rd
|
0.39
53rd
|
| Defensive interval (days) | 354 days
50th
|
256 days
33rd
|
794 days
74th
|
Leverage & solvency (latest quarter)
13 measures| Measure | STE | ALC | THC |
|---|---|---|---|
| Total debt | $2.0B
67th
|
$5.3B
100th
|
$13.2B
97th
|
| Debt / equity | 0.28
67th
|
0.25
50th
|
2.84
86th
|
| Net debt / equity | 0.22
67th
|
0.18
50th
|
2.38
89th
|
| Debt / assets | 19.0%
67th
|
17.0%
50th
|
43.2%
69th
|
| Debt / capital | 22.1%
67th
|
19.7%
50th
|
74.0%
86th
|
| Debt / EBITDA | 1.25 | 2.08 | 2.62
46th
|
| Net debt / EBITDA | 0.96 | 1.51 | 2.19
50th
|
| Interest coverage (EBIT / interest) | 18.8x
100th
|
4.3x
50th
|
5.1x
43rd
|
| Cash interest coverage | 21.3x
100th
|
10.9x
80th
|
4.9x
40th
|
| Debt payback (years of OCF) | 1.6 yrs
25th
|
2.3 yrs
75th
|
3.3 yrs
45th
|
| Liabilities / assets | 32.7%
33rd
|
30.6%
17th
|
71.6%
69th
|
| IS credit model rating | AA | A- | BBB |
| Implied credit spread (bps) | 80
0th
|
175
33rd
|
275
53rd
|
Efficiency
11 measures| Measure | STE | ALC | THC |
|---|---|---|---|
| Asset turnover | 0.57
83rd
|
0.35
17th
|
0.73
19th
|
| Fixed asset turnover | 2.78
33rd
|
2.06
17th
|
3.49
48th
|
| Inventory turnover | 5.0
100th
|
1.9
17th
|
47.2
60th
|
| Receivables turnover | 6.2
33rd
|
5.3
0th
|
8.5
41st
|
| Days sales outstanding | 59 days
67th
|
69 days
100th
|
43 days
59th
|
| Days inventory outstanding | 74 days
0th
|
190 days
83rd
|
8 days
44th
|
| Days payables outstanding | 35 days
17th
|
72 days
83rd
|
31 days
69th
|
| Cash conversion cycle (days) | 98 days
0th
|
187 days
67th
|
20 days
47th
|
| Capex / revenue | 6.0%
80th
|
5.5%
40th
|
4.5%
71st
|
| Capex / depreciation | 0.74
60th
|
0.36
40th
|
1.11
71st
|
| Operating expense ratio | 26.7%
0th
|
58.9%
50th
|
0.0%
0th
|
Cash flow & earnings quality
7 measures| Measure | STE | ALC | THC |
|---|---|---|---|
| Operating cash flow / net income | 1.60 | 3.56 | 1.79
65th
|
| FCF / net income | 1.15 | 2.63 | 1.35
52nd
|
| FCF / operating cash flow | 71.8% | 73.9% | 75.3%
50th
|
| Capex / operating cash flow | 28.2% | 26.1% | 24.7%
50th
|
| Accruals ratio | -4.6%
67th
|
-5.2%
50th
|
-6.0%
56th
|
| Sloan accruals ratio | -4.3%
50th
|
-6.7%
17th
|
-5.6%
34th
|
| Earnings quality score (0-1) | 1.00 | 0.75 | 0.75
9th
|
Scores & forensic checks
15 measures| Measure | STE | ALC | THC |
|---|---|---|---|
| IS score | 69
100th
|
46
50th
|
63
69th
|
| IS profitability | 53
83rd
|
22
50th
|
56
81st
|
| IS growth | 63
80th
|
27
0th
|
66
56th
|
| IS value | 51
100th
|
49
67th
|
67
88th
|
| IS momentum | 90
100th
|
60
40th
|
88
66th
|
| IS risk (safety) | 100
67th
|
65
50th
|
50
19th
|
| IS quality | 81
100th
|
68
50th
|
61
50th
|
| IS balance sheet | 72
67th
|
63
50th
|
36
34th
|
| IS earnings quality | 74
83rd
|
70
67th
|
76
66th
|
| IS cash flow | 63
83rd
|
63
67th
|
69
75th
|
| Piotroski F-score (0-9) | 8
83rd
|
6
67th
|
7
59th
|
| Altman Z-score | 5.0
83rd
|
2.6
50th
|
1.9
22nd
|
| Beneish M-score | −2.47
80th
|
−2.77
40th
|
−1.11
88th
|
| Ohlson O-score | −9.77
17th
|
−9.79
0th
|
−7.49
38th
|
| IS credit score | 88
100th
|
68
67th
|
59
44th
|
Size (TTM)
8 measures| Measure | STE | ALC | THC |
|---|---|---|---|
| Market cap | $21.7B
83rd
|
$32.0B
100th
|
$21.5B
97th
|
| Revenue | $6.0B
83rd
|
$10.8B
100th
|
$21.8B
94th
|
| EBITDA | $1.6B
83rd
|
$2.6B
100th
|
$5.1B
97th
|
| Net income | $805.1M
100th
|
$639.3M
83rd
|
$2.2B
97th
|
| Free cash flow | $925.6M
83rd
|
$1.7B
100th
|
$3.0B
97th
|
| Total assets | $10.7B
83rd
|
$31.1B
100th
|
$30.7B
97th
|
| Shareholders' equity | $7.2B
83rd
|
$21.6B
100th
|
$4.7B
97th
|
| Employees | 17,937
83rd
|
25,000
100th
|
88,500
94th
|
Price performance
9 measures| Measure | STE | ALC | THC |
|---|---|---|---|
| 1 day | −0.8% | −0.6% | −2.9% |
| 1 week | +3.9% | +3.2% | +1.3% |
| 1 month | +7.0% | +1.6% | +2.0% |
| 3 months | +3.8% | −5.5% | +37.5% |
| 6 months | −1.4% | −18.6% | +35.9% |
| Year to date | −10.7% | −14.7% | +34.0% |
| 1 year | −5.7% | −10.5% | +34.1% |
| 3 years, cumulative | +1.2% | −12.3% | +363.2% |
| 5 years, cumulative | +5.6% | −14.6% | +332.0% |
Technicals
4 measures| Measure | STE | ALC | THC |
|---|---|---|---|
| RSI 14 | 62.1 | 53.0 | 55.0 |
| From 52-week high | −17.2% | −24.5% | −5.6% |
| From 52-week low | +14.1% | +7.0% | +69.6% |
| Beta | 0.93 | 0.73 | 1.20 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17